These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30470147)

  • 1. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
    Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
    Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
    Tytgat GN; Simoneau G
    Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
    De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
    Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
    Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
    Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1014-1021. PubMed ID: 32343001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
    Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
    Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
    Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
    Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
    Mandel KG; Daggy BP; Brodie DA; Jacoby HI
    Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
    Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients.
    Kwiatek MA; Roman S; Fareeduddin A; Pandolfino JE; Kahrilas PJ
    Aliment Pharmacol Ther; 2011 Jul; 34(1):59-66. PubMed ID: 21535446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms.
    Yuan YZ; Fang JY; Zou DW; Levinson N; Jenner B; Wilkinson J
    J Dig Dis; 2016 Nov; 17(11):725-734. PubMed ID: 27622897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Can acid pocket-targeting alginate-antacid (Gaviscon Double Action) relieve upper gastrointestinal symptoms in gastro-oesophageal reflux disease?].
    Kim SE; Park MI
    Korean J Gastroenterol; 2014 Jun; 63(6):386-8. PubMed ID: 25097964
    [No Abstract]   [Full Text] [Related]  

  • 13. The suppression of gastro-oesophageal reflux by alginates.
    Dettmar PW; Hampson FC; Taubel J; Lorch U; Johnstone LM; Sykes J; Berry PJ
    Int J Clin Pract; 2007 Oct; 61(10):1654-62. PubMed ID: 17681004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vivo anti-reflux and raft properties of alginates.
    Lambert JR; Korman MG; Nicholson L; Chan JG
    Aliment Pharmacol Ther; 1990 Dec; 4(6):615-22. PubMed ID: 2129648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of food and acid reflux in patients with low-grade oesophagitis--the role of an anti-reflux agent.
    Washington N; Steele RJ; Jackson SJ; Washington C; Bush D
    Aliment Pharmacol Ther; 1998 Jan; 12(1):53-8. PubMed ID: 9692701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
    Coyle C; Crawford G; Wilkinson J; Thomas SJ; Bytzer P
    Aliment Pharmacol Ther; 2017 Jun; 45(12):1524-1533. PubMed ID: 28464343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants.
    Corvaglia L; Aceti A; Mariani E; De Giorgi M; Capretti MG; Faldella G
    Aliment Pharmacol Ther; 2011 Feb; 33(4):466-70. PubMed ID: 21158879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children.
    Buts JP; Barudi C; Otte JB
    Eur J Pediatr; 1987 Mar; 146(2):156-8. PubMed ID: 3032640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease.
    Chatfield S
    Curr Med Res Opin; 1999; 15(3):152-9. PubMed ID: 10621921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects].
    Uspenskiĭ IuP; Pakhomova IG; Bubiakina VN
    Eksp Klin Gastroenterol; 2008; (1):96-101. PubMed ID: 19145860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.